H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

CEO

Mr. Charl van Zyl

Employees

5707

Country

United States

ISIN

DK0061804770

Listings

0 Comments

Share your thoughts

FAQ

What is H. Lundbeck AS stock price today?▼

The current price of HLBBF is $6.60 USD — it has decreased by -2.21% in the past 24 hours. Watch H. Lundbeck AS stock price performance more closely on the chart.

What is H. Lundbeck AS stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange H. Lundbeck AS stocks are traded under the ticker HLBBF.

Is H. Lundbeck AS stock price growing?▼

HLBBF stock has fallen by -9.47% compared to the previous week, the month change is a -7.82% fall, over the last year H. Lundbeck AS has showed a +23.36% increase.

What is H. Lundbeck AS revenue for the last year?▼

H. Lundbeck AS revenue for the last year amounts to 7.66B USD.

What is H. Lundbeck AS net income for the last year?▼

HLBBF net income for the last year is 988.97M USD.

Does H. Lundbeck AS pay dividends?▼

Yes, HLBBF dividends are paid annual. The last dividend per share was 0.18 USD. As of today, Dividend Yield (FWD)% is 2.7%.

How many employees does H. Lundbeck AS have?▼

As of June 20, 2026, the company has 5,707 employees.

In which sector is H. Lundbeck AS located?▼

H. Lundbeck AS operates in the Health & Wellness sector.

When did H. Lundbeck AS complete a stock split?▼

H. Lundbeck AS has not had any recent stock splits.

Where is H. Lundbeck AS headquartered?▼

H. Lundbeck AS is headquartered in Valby, United States.